IL114151A - Insulin analog formulations - Google Patents

Insulin analog formulations

Info

Publication number
IL114151A
IL114151A IL11415195A IL11415195A IL114151A IL 114151 A IL114151 A IL 114151A IL 11415195 A IL11415195 A IL 11415195A IL 11415195 A IL11415195 A IL 11415195A IL 114151 A IL114151 A IL 114151A
Authority
IL
Israel
Prior art keywords
insulin analog
analog formulations
formulations
insulin
analog
Prior art date
Application number
IL11415195A
Other languages
English (en)
Other versions
IL114151A0 (en
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22989969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL114151(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL114151A0 publication Critical patent/IL114151A0/xx
Publication of IL114151A publication Critical patent/IL114151A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL11415195A 1994-06-16 1995-06-14 Insulin analog formulations IL114151A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/260,634 US5474978A (en) 1994-06-16 1994-06-16 Insulin analog formulations

Publications (2)

Publication Number Publication Date
IL114151A0 IL114151A0 (en) 1995-10-31
IL114151A true IL114151A (en) 2000-09-28

Family

ID=22989969

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11415195A IL114151A (en) 1994-06-16 1995-06-14 Insulin analog formulations

Country Status (38)

Country Link
US (1) US5474978A (de)
JP (2) JP3171541B2 (de)
KR (1) KR100382326B1 (de)
CN (1) CN1105576C (de)
AT (1) AT408720B (de)
BE (1) BE1009408A5 (de)
BR (1) BR9502795A (de)
CA (1) CA2151560C (de)
CH (2) CH689250A5 (de)
CO (1) CO4410203A1 (de)
CZ (1) CZ287484B6 (de)
DE (1) DE19521720B4 (de)
DK (1) DK173015B1 (de)
ES (1) ES2091727B1 (de)
FI (1) FI118207B (de)
FR (2) FR2721214B1 (de)
GB (1) GB2291427B (de)
GR (1) GR1003004B (de)
HU (1) HU227240B1 (de)
IE (1) IE68853B1 (de)
IL (1) IL114151A (de)
IT (1) IT1276723B1 (de)
LU (1) LU88626A1 (de)
MY (1) MY115631A (de)
NL (1) NL1000566C2 (de)
NO (1) NO322128B1 (de)
NZ (1) NZ272359A (de)
PE (1) PE19496A1 (de)
PL (1) PL181310B1 (de)
PT (1) PT101722B (de)
RO (1) RO113530B1 (de)
RS (1) RS49577B (de)
RU (1) RU2152399C2 (de)
SE (1) SE509052C2 (de)
SI (1) SI9500200A (de)
TW (1) TW421596B (de)
UA (1) UA26874C2 (de)
ZA (1) ZA954943B (de)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5836705A (en) * 1992-07-27 1998-11-17 Choate; John I. M. Keyboard arrangement to maximize typing speed and data entry and to ease transition from a qwerty keyboard
US5352050A (en) * 1992-07-27 1994-10-04 Choate John I M Keyboard arrangement to maximize typing speed and ease of transition from a QWERTY keyboard
US5498088A (en) * 1992-07-27 1996-03-12 Choate; John I. M. Keyboard arrangement to maximize typing speed and ease of transition from a qwerty keyboard
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
AU6299596A (en) * 1995-06-30 1997-02-05 Novo Nordisk A/S Prevention of a disease having the characteristics of diabetes
ES2167751T5 (es) * 1996-06-20 2012-03-30 Novo Nordisk A/S Preparaciones de insulina conteniendo un halogenuro
UA72427C2 (en) * 1996-06-20 2005-03-15 Novo Nordisk As Water-soluble insulin preparation containing mannite, method for manufacturing composition containing soluble insulin or crystalline insulin
ZA984697B (en) 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
SV1998000125A (es) 1997-10-24 1999-05-24 Lilly Co Eli Composiciones de insulina insoluble ref. x-11232
US6531448B1 (en) 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
EP1044016B1 (de) * 1998-01-09 2005-03-16 Novo Nordisk A/S Stabilisierte insulin-zubereitungen
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
EP1172114B1 (de) * 1998-10-16 2004-09-29 Novo Nordisk A/S Stabile konzentrierte Insulin Präparationen zur pulmonaren Verabreichung
ATE216258T1 (de) * 1998-10-16 2002-05-15 Novo Nordisk As Insulin präparationen enthaltend methanol zur pulmonaren verabreichung
US6635617B1 (en) 1998-10-16 2003-10-21 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
US6489292B1 (en) 1998-11-18 2002-12-03 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
WO2000029013A1 (en) * 1998-11-18 2000-05-25 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
WO2001052937A1 (en) 2000-01-24 2001-07-26 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
AU8436401A (en) * 2000-07-31 2002-02-13 Univ Bar Ilan Methods and pharmaceutical compositions for healing wounds
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US6737401B2 (en) * 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
RU2202365C2 (ru) * 2001-07-20 2003-04-20 Институт биоорганической химии им. М.М.Шемякина и Ю.А.Овчинникова РАН Способ приготовления быстродействующего раствора инсулина для инъекций
ES2412306T3 (es) 2002-01-09 2013-07-11 Emisphere Technologies, Inc. Polimorfos de 4-((4-cloro-2-hidroxibenzoil)amino)butanoato de sodio
US20040005999A1 (en) * 2002-03-07 2004-01-08 Andreasen Kasper Huus Polyamino acid-based particle insulin preparation
US20030211976A1 (en) * 2002-03-07 2003-11-13 Andreasen Kasper Huus Polyamino acid-based particle insulin formulation
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
PT1633876E (pt) 2003-06-17 2008-11-03 Sembiosys Genetics Inc Métodos para a produção de insulina em plantas
US20060241019A1 (en) * 2003-07-25 2006-10-26 Bridon Dominique P Long lasting insulin derivatives and methods thereof
AU2005209199B2 (en) * 2004-01-16 2008-09-11 Biodel Inc. Sublingual drug delivery device
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
CN102001962B (zh) 2004-05-06 2013-04-03 爱密斯菲尔科技公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钠的晶体的多晶
WO2005117854A2 (en) * 2004-05-14 2005-12-15 Emisphere Technologies, Inc. Aryl ketone compounds and compositions for delivering active agents
US20080044481A1 (en) * 2004-05-27 2008-02-21 Mordechai Harel Microparticles for Oral Delivery
PL2626368T3 (pl) 2004-07-19 2017-06-30 Biocon Limited Koniugaty insulina-oligomer, ich formulacje i zastosowania
JP2008509145A (ja) * 2004-08-03 2008-03-27 エミスフィアー テクノロジーズ インコーポレイテッド 抗糖尿病性経口インスリン−ビグアニドの組み合わせ
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US20060078623A1 (en) * 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
ES2779957T3 (es) * 2004-10-05 2020-08-20 Novo Nordisk As Preparación farmacéutica que contiene insulina en forma cristalina así como también solubilizada
JP4874989B2 (ja) 2004-11-22 2012-02-15 ノヴォ ノルディスク アー／エス 可溶性で安定なインスリン含有調合物
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
JPWO2006093222A1 (ja) * 2005-03-02 2008-08-07 味の素株式会社 インスリンの多量体形成阻害剤
ZA200802546B (en) 2005-08-29 2009-10-28 Healor Ltd Methods and compositions for prvention and treatment of diabetic and aged skin
RU2507196C2 (ru) 2005-09-19 2014-02-20 Эмисфире Текнолоджис, Инк. Кристаллические формы динатриевой соли n-(5-хлорсалицилоил)-8-аминокаприловой кислоты
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
EP1991575A1 (de) * 2006-02-21 2008-11-19 Novo Nordisk A/S Einkettige insulinanaloga und pharmazeutische formulierungen daraus
MX2008013165A (es) 2006-04-12 2009-01-29 Biodel Inc Formulaciones de combinacion de insulina de accion rapida y accion larga.
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
EP2074140B8 (de) 2006-10-04 2015-10-28 Case Western Reserve University Fibrillationsresistentes insulin und insulinanaloga
CA3013149C (en) 2007-03-13 2021-12-07 Jds Therapeutics, Llc Methods and compositions for the sustained release of chromium
WO2008116141A1 (en) * 2007-03-21 2008-09-25 Emisphere Technologies, Inc. Allylqxy and alkyloxy benzoic acid delivery agents
EP2514412A1 (de) * 2007-04-30 2012-10-24 Novo Nordisk A/S Hochkonzentrierte Insulinlösungen und -zusammensetzungen
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
DK2203181T3 (en) 2007-10-16 2018-05-28 Biocon Ltd An orally administrable solid composition and a method thereof
AU2008318423B2 (en) 2007-11-02 2013-12-05 Emisphere Technologies, Inc. Method of treating vitamin B12 deficiency
WO2010014946A2 (en) 2008-07-31 2010-02-04 Case Western Reserve University Halogen-stabilized insulin
US8354435B2 (en) 2008-09-08 2013-01-15 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
LT3228320T (lt) 2008-10-17 2020-03-10 Sanofi-Aventis Deutschland Gmbh Insulino ir glp-1 agonisto derinys
WO2010062308A1 (en) 2008-10-28 2010-06-03 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
NZ594248A (en) 2009-01-28 2015-03-27 Smartcells Inc Conjugate based systems for controlled drug delivery
CA2750252A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
RU2011137413A (ru) 2009-02-12 2013-03-20 Проекто Де Биомедисина Сима, С.Л. Применение кардиотрофина-1 для лечения метаболических заболеваний
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
US8623345B2 (en) 2009-03-20 2014-01-07 Smartcells Terminally-functionalized conjugates and uses thereof
PE20121362A1 (es) 2009-11-13 2012-10-17 Sanofi Aventis Deutschland Composicion farmaceutica que comprende despro36exendina-4(1-39)-lys6-nh2, insulina gly(a21)-arg(b31)-arg(b32) y metionina
KR101772372B1 (ko) 2009-11-13 2017-08-29 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
EP2523677A2 (de) 2010-01-11 2012-11-21 Healor Ltd. Verfahren zur behandlung von entzündungskrankheiten und -erkrankungen
KR20130026429A (ko) * 2010-02-24 2013-03-13 에미스페어 테크놀로지스, 인코포레이티드 경구 ｂ12 치료요법
EP2611458B1 (de) 2010-08-30 2016-09-21 Sanofi-Aventis Deutschland GmbH Verwendung von ave0010 für die herstellung eines medikaments zur behandlung von diabetes mellitus typ 2
CN107759771A (zh) 2010-09-30 2018-03-06 索尔维公司 天然来源的环氧氯丙烷的衍生物
WO2012115641A1 (en) 2011-02-23 2012-08-30 Elona Biotechnologies Lis-pro proinsulin compositions and methods of producing lis-pro insulin analogs therefrom
MX344925B (es) 2011-03-01 2017-01-11 N21 Acquisition Holding Llc Composiciones de insulina y cromo para el tratamiento y prevención de diabetes, hipoglucemia y alteraciones relacionadas.
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AU2012300978B2 (en) 2011-08-29 2017-04-27 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
SG11201401835VA (en) 2011-10-27 2014-09-26 Univ Case Western Reserve Ultra-concentrated rapid-acting insulin analogue formulations
WO2014004278A1 (en) * 2012-06-26 2014-01-03 The Curators Of The University Of Missouri Photocleavable drug conjugates
EP2877200B1 (de) 2012-07-17 2019-05-08 Case Western Reserve University O-verknüpfte kohlenhydratmodifizierte insulinanaloga
EP2919804B1 (de) 2012-11-13 2018-01-31 Adocia Schnell wirkende insulinformulierung mit einer anionischen substituierten verbindung
US9707276B2 (en) 2012-12-03 2017-07-18 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
AU2013365945B2 (en) 2012-12-19 2017-03-02 Wockhardt Limited A stable aqueous composition comprising human insulin or an analogue or derivative thereof
CA2889162A1 (en) 2012-12-26 2014-07-03 Wockhardt Limited Pharmaceutical composition
US9670162B2 (en) 2013-03-14 2017-06-06 The Board Of Trustees Of The Leland Stanford Junio Mitochondrial aldehyde dehyrogenase-2 modulators and methods of use thereof
AR098168A1 (es) 2013-10-25 2016-05-04 Sanofi Sa Formulación estable de insulina glulisina
US10124040B2 (en) 2014-08-26 2018-11-13 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin or insulin analog compositions
HRP20230470T1 (hr) 2014-12-12 2023-07-21 Sanofi-Aventis Deutschland Gmbh Formulacija fiksnog omjera inzulin glargin/liksisenatid
AR102869A1 (es) 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
MX2018009748A (es) 2016-02-11 2019-02-07 Nutrition 21 Llc Composiciones que contienen cromo para mejorar la salud y el estado físico.
NZ758298A (en) 2017-06-01 2022-11-25 Lilly Co Eli Rapid-acting insulin compositions
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery
US11820805B2 (en) 2017-12-18 2023-11-21 Merck Sharp & Dohme Llc Conjugate based systems for controlled insulin delivery
CA3157995A1 (en) 2019-10-25 2021-04-29 Cercacor Laboratories, Inc. Indicator compounds, devices comprising indicator compounds, and methods of making and using the same
AU2021247169A1 (en) 2020-03-31 2022-10-20 Protomer Technologies Inc. Conjugates for selective responsiveness to vicinal diols
US20240374735A1 (en) 2020-11-19 2024-11-14 Protomer Technologies Inc. Aromatic boron-containing compounds and insulin analogs
US12139502B2 (en) 2022-05-18 2024-11-12 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
DE2933946A1 (de) * 1979-08-22 1981-03-12 Hoechst Ag, 6000 Frankfurt Insulinkristallsuspension und verfahren zu ihrer herstellung.
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4608634A (en) * 1982-02-22 1986-08-26 Texas Instruments Incorporated Microcomputer with offset in store-accumulator operations
DK347086D0 (da) * 1986-07-21 1986-07-21 Novo Industri As Novel peptides
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
EP0425482B1 (de) * 1988-07-20 1993-08-18 Novo Nordisk A/S Menschliche insulinanalage und zubereitungen daraus
JPH04502465A (ja) * 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
NZ232375A (en) * 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
DK0705275T3 (da) * 1993-06-21 1999-09-20 Novo Nordisk As AspB28-insulin-krystaller
HU217684B (hu) * 1993-09-17 2000-03-28 Novo Nordisk A/S Acilezett inzulinszármazékok és azokat tartalmazó gyógyszerkészítmények és előállításuk
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5597893A (en) * 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina

Also Published As

Publication number Publication date
CZ287484B6 (en) 2000-12-13
SI9500200A (en) 1996-02-29
PE19496A1 (es) 1996-06-01
NO952357D0 (no) 1995-06-14
ZA954943B (en) 1997-09-14
HU9501716D0 (en) 1995-08-28
NO322128B1 (no) 2006-08-21
SE9502167D0 (sv) 1995-06-14
DE19521720A1 (de) 1995-12-21
NL1000566A1 (nl) 1995-12-18
NL1000566C2 (nl) 1996-12-03
IE950436A1 (en) 1995-12-27
FI952931A0 (fi) 1995-06-14
US5474978A (en) 1995-12-12
FI118207B (fi) 2007-08-31
NZ272359A (en) 1996-10-28
ATA101695A (de) 2001-07-15
RU2152399C2 (ru) 2000-07-10
FI952931L (fi) 1995-12-17
CN1105576C (zh) 2003-04-16
JPH083067A (ja) 1996-01-09
PT101722B (pt) 1997-02-28
TW421596B (en) 2001-02-11
GR950100229A (en) 1996-02-29
FR2741078A1 (fr) 1997-05-16
MY115631A (en) 2003-08-30
PL181310B1 (pl) 2001-07-31
YU39695A (sh) 1997-08-22
GB2291427B (en) 1998-09-16
BE1009408A5 (fr) 1997-03-04
ITMI951278A0 (it) 1995-06-14
IT1276723B1 (it) 1997-11-03
IE68853B1 (en) 1996-07-24
FR2721214B1 (fr) 1997-09-26
DK173015B1 (da) 1999-11-15
CN1122248A (zh) 1996-05-15
RS49577B (sr) 2007-04-10
CH689250A5 (de) 1999-01-15
PL309098A1 (en) 1995-12-27
HK1015138A1 (en) 1999-10-08
UA26874C2 (uk) 1999-12-29
DE19521720B4 (de) 2009-09-03
CO4410203A1 (es) 1997-01-09
FR2741078B1 (fr) 1998-08-07
AU2168095A (en) 1996-01-04
DK67795A (da) 1995-12-17
GB9512038D0 (en) 1995-08-09
CZ154295A3 (en) 1996-02-14
LU88626A1 (fr) 1996-02-01
PT101722A (pt) 1995-12-29
ES2091727B1 (es) 1998-02-01
GB2291427A (en) 1996-01-24
JP3171541B2 (ja) 2001-05-28
KR100382326B1 (ko) 2003-07-07
ITMI951278A1 (it) 1996-12-14
IL114151A0 (en) 1995-10-31
CH689935A5 (de) 2000-02-15
CA2151560A1 (en) 1995-12-17
AU694501B2 (en) 1998-07-23
KR960000924A (ko) 1996-01-25
ES2091727A1 (es) 1996-11-01
GR1003004B (el) 1998-11-05
NO952357L (no) 1995-12-18
SE9502167L (sv) 1995-12-17
FR2721214A1 (fr) 1995-12-22
RO113530B1 (ro) 1998-08-28
AT408720B (de) 2002-02-25
HU227240B1 (en) 2010-12-28
BR9502795A (pt) 1996-03-12
SE509052C2 (sv) 1998-11-30
HUT73186A (en) 1996-06-28
CA2151560C (en) 2000-05-09
RU95110109A (ru) 1997-05-10
JP2001199899A (ja) 2001-07-24

Similar Documents

Publication Publication Date Title
GB2291427B (en) Insulin analog formulations
GB2290294B (en) Monomeric insulin analog formulations
IL117696A0 (en) Monomeric insulin analog formulations
ZA953236B (en) Pharmaceutical formulations
IL133348A0 (en) Stable insulin formulations
GB9404248D0 (en) Pharmaceutical formulations
AU694501C (en) Insulin analog formulations
AU731636C (en) Insulin analog formulations
EG26644A (en) Preparations of monoclonal insulin analogs
GB2327424B (en) Monomeric insulin analog formulations
HK1015138B (en) Insulin analog formulations
GB9413542D0 (en) Pharmaceutical formulations
AU2168295A (en) Monomeric insulin analog formulations
AU738101C (en) Monomeric insulin analog formulations
GB9408419D0 (en) Formulations
GB9409464D0 (en) Formulations
GB9406050D0 (en) Formulations
GB9408163D0 (en) Pharmaceutical formulations
GB9408162D0 (en) Pharmaceutical formulations
GB9426113D0 (en) Pharmaceutical formulations
GB9408164D0 (en) Pharmaceutical formulations
GB9401738D0 (en) Pharmaceutical formulations
GB9417953D0 (en) Pharmaceutical formulations
GB9414216D0 (en) Pharmaceutical formulations
GB9408151D0 (en) Pharmaceutical formulations

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired